Drug Hunter Interview
Drug Hunter Flash Talk with Prof. Hande Ozdinler, Ph.D. and Prof. Richard B. Silverman, Ph.D.
A Long Swim
A Long Swim co-founder and executive director Doug McConnell sits down with Dr. Hande Ozdinler, A Long Swim Director of Science and Associate Professor of Neurology at Northwestern University, and Dr. Richard Silverman, Professor of Chemistry & Molecular Biosciences at Northwestern University, to discuss their most recent discovery of NU-9, the first compound that improves...
Akava receives Orphan Drug Designation status for AKV9
Akava Therapeutics, LLC announces that on July 6, 2022, orphan drug designation (ODD) status was received for AKV9 for the treatment of amyotrophic lateral sclerosis (ALS) from the U.S. Food and Drug Administration (FDA), pursuant to section 526 of the Federal, Drug and Cosmetic Act (12 U.S.C.360bb). Obtaining orphan drug designation represents a significant company...
This time around, Lyrica’s inventor is developing his Northwestern discoveries at his own biotech
Richard Silverman was left in the dark for the last five years of clinical development of the drug he discovered. The Northwestern University professor found out about the first approval…
NU‑9 improves health of hSOD1G93A mouse upper motor neurons in vitro, especially in combination with riluzole or edaravone
A paper has recently been published demonstrating that AKV9 improves the health of mutant SOD1 mouse upper motor neurons in vitro much better than the FDA-approved ALS drugs riluzole and edaravone, and the combination of AKV9 with either of those drugs provides an additive effect.
AKAVA Founder, Richard B. Silverman receives 2021 Tetrahedron Prize
Our Founder, Richard B. Silverman, was selected to receive the 2021 Tetrahedron Prize for Creativity in Organic Chemistry and will present a lecture at the Tetrahedron Symposium in Lisbon, Portugal this June.